QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kintara-therapeutics-provides-update-on-rem-001-clinical-study-has-enrolled-4-of-the-10-patients-needed-to-reach-the-minimum-patient-enrollment-to-assess-safety-and-appropriate-phase-3-dose-with-several-other-patients-identified-as-study-candidates-at-kintaras-clinical-sites-no-treatment-related-safety-issues-have-been-identified-to-date-and-assessment-of-the-appropriate-phase-3-dose-is-ongoing

REM-001 Clinical Study UpdateAs of September 10, 2024, the REM-001 study in patients with cutaneous metastatic breast cancer (C...

 kintara-therapeutics-to-hold-special-meeting-for-completion-of-proposed-merger-with-tuhura-biosciences

Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count

Core News & Articles

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel t...

 tuhura-biosciences-and-kintara-therapeutics-announce-phase-1b-trial-of-ifx-20-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcinoma-and-cutaneous-squamous-cell-carcinoma-results

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeksEighty percent (80%) of ICI ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION